SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...


Embrex, now a part of Zoetis (NYSE: ZTS), a global animal health company, developed and launched the world’s first commercial in ovo vaccination device more than 20 years ago. Its Inovoject® System is considered to be the industry standard for in ovo technology, revolutionized automation in the hatchery. Pfizer’s animal health division acquired Embrex in 2007.
Website